Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027

Zura Bio Ltd

2025-Q2 EPS reported -$0.36

Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.
Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.
R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.
Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.
Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.